Marilou Inocalla, MD
Psychiatry · Wytheville, VANPI 1932163375
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 503 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 503 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$950
- AbbVie$858
- Neurocrine Biosciences, Inc.$590
- plus $2K from 13 others
What the payments were for
- Food & beverage$8,01592%
- Education$7108%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 107 | $1,880 |
| Alkermes, Inc. | 75 | $1,491 |
| Otsuka America Pharmaceutical, Inc. | 71 | $1,166 |
| Johnson & Johnson | 51 | $950 |
| AbbVie(2 entities) | 71 | $858 |
| Neurocrine Biosciences, Inc. | 33 | $590 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $547 |
| Sunovion Pharmaceuticals Inc. | 17 | $250 |
| Lundbeck LLC | 13 | $225 |
| E.r. Squibb & Sons, L.L.C. | 10 | $213 |
| Vanda Pharmaceuticals Inc. | 10 | $185 |
| Corium, LLC | 7 | $155 |
| Axsome Therapeutics, Inc. | 4 | $69 |
| Supernus Pharmaceuticals, Inc. | 3 | $40 |
| Merck | 2 | $29 |
| USWM, LLC | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Indivior Inc. | 1 | $18 |
| Eisai Inc. | 1 | $13 |
How this compares
$8,725 in reported general payments places this provider in the 90th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 69 | $249,819 |
| VraylarCariprazine Hcl | 78 | $114,215 |
| IngrezzaValbenazine Tosylate | 13 | $109,650 |
| RexultiBrexpiprazole | 49 | $87,954 |
| Abilify MaintenaAripiprazole | 22 | $63,053 |
| AristadaAripiprazole Lauroxil | 18 | $46,878 |
| GeodonZiprasidone Hcl | 11 | $25,892 |
| Lurasidone Hcl | 36 | $23,039 |
| CaplytaLumateperone Tosylate | 12 | $19,794 |
| Aripiprazole | 132 | $14,028 |
| TrintellixVortioxetine Hydrobromide | 21 | $11,110 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $7,530 |
| Paliperidone ErPaliperidone | 22 | $6,857 |
| Asenapine Maleate | 17 | $5,833 |
| Quetiapine Fumarate | 423 | $5,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $950 | $249,81969 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,166 | $151,00771 claims |
| AbbVieVraylar | $858 | $114,21578 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $590 | $109,65013 claims |
| Alkermes, Inc.Aristada | $1,491 | $46,87818 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $547 | $19,79412 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $22 | $18,63940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Wytheville
- Maria AbeledaWytheville$8K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- David SpiegelNorfolk$565K
- William YetterVirginia Beach$312K
- Anita ClaytonCharlottesville$260K
- Robert GardellaStaunton$201K
- Timothy KaneStaunton$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.